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These results show changes both in receptor sub-type and functional cou-
pling to G-proteins, associated with arterio-venous grafting, possibly reflect-
ing changes in smooth muscle cell phenotype.
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LV remodeling (enlargement, sphericity and myocyte hypertrophy), is a key
process in the progressive deterioration of LV function observed in heart fail-
ure (HF). In dogs with moderate HF (LV ejection fraction 30--40%), we pre-
viously showed that early, long-term (3 months) monotherapy with enalapril
(ENA, 10 mg bid, n = 7) and metoprolol (MET, 25 mg bid, n = 7) but not
digoxin (DIG, 0.25 mg qd, n = 7) prevented the progressive LV enlargement
observed in untreated dogs (CON, n = 7). In the present study, we used the
same cohorts of dogs to examine the effects of these agents on myocyte
hypertrophy. Myocyte cross-sectional area (MCSA) was evaluated histologi-
cally from frozen LV sections obtained at the end of therapy. From each sec-
tion, 5 fields (radial orientation). each containing at least 100 myocytes, were
selected randomly for analysis using computer-based planimetry. LV tissue
from 7 normal (NL) dogs was used for comparison.
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Conclusions. Stroke volume was preserved through increased LV volume
and elevated LVEDP in dogs with DC shocks. OPC-21268 effectively reduced
preload and afterload, resulting in smaller LV cavity and normal LVEDP while
maintaining stroke volume.
MCSA was larger in CON, MET and DIG dogs compared to NL and ENA
dogs I'P < 0.05). No significant difference was present in MeSA between
ENA and NL dogs. Only ENA attenuated myocyte hypertrophy in dogs with
moderate HF.
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Although little is known about the pharmacology of the smooth muscle cells
of human saphenous vein coronary artery bypass grafts, there is evidence
to suggest that the function of G-proteins and alpha-adrenergic receptors is
altered. This study examines the alpha-adrenergic function of smooth mus-
cle cells of aorto-coronary vein bypass grafts and saphenous veins obtained
from eight patients undergoing repeat coronary artery bypass grafting for re-
current ischemic symptoms. After removal from the patient, each specimen
was placed into oxygenated Krebs solution, rapidly cleaned, dissected and
patent segments sectioned into 5 mm rings (4 per vessel) for isometric ten-
sion studies to phenylephrine (1 0-10 to 10-4M) alone and in the presence of
the alpha-adrenergic 1A antagonist WB41 01, the 1B antagonist chloroethyl-
clonidine, and the G-protein inhibitor, pertussis toxin. The results suggest
that the saphenous veins have a homogenous population of alpha adrenergic
population (1 B) which are coupled to pertussis toxin insensitive G-proteins
(Table). The retrieved vein grafts show a predominantly homogenous alpha
adrenergic population (1 A). which are coupled to pertussis toxin sensitive
G-proteins (Table).
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Myocardial ischemia induces adenosine (ADO) formation that limits injury.
Amplification of ADO levels (via exogenous ADO, ischemic preconditioning,
or an ARA, etc) provides more protection. A new novel orally-active ARA
GP531 (5-amino-1-B-D-[5-benzylamino- 5- deoxy ribofuranosyl]imidazole-4
carboxamide) augments ADO levels specifically during periods of ATP break-
down, ego ischemia, so its effect on cardiac myocytes was evaluated. Rabbit
myocytes paced at 1 Hz were exposed to a simulated ischemic buffer con-
taining (mMI 2'-deoxyglucose (201, NaCN (1), Na-Iactate (20), and K+ (10) at
pHo 6.6 (3rC) for 8 min followed by 15 min reperfusion in non-ischemic
buffer. Changes of myocyte length were monitored with an optical-video
edge recording system, and hypercontracture was the index of irreversible
cell injury. In the absence of GP-1-531, 58 ± 7% Icells studied = 132) of
the myocytes developed hypercontracture, and the surviving myocytes con-
tracted at 43 ± 9% of pre-ischemic levels. GP531 had no effect on myocytes
basal function but reduced cell hypercontracture to 49 ± 5% 10.5 I'M, cells
= 134, P = NS). 35 ± 5% (5 I'M, cells = 157, p < 0.05). and 34 ± 7%
(50 I'M, cells = 139, P < 0.05), respectively, and the surviVing myocytes
contracted at 66 ± 5% of pre-ischemic levels (p < 0.05 vs untreated con-
trolsl. Moreover, GP531-induced cardioprotection was blocked by the non-
selective adenosine-receptor antagonist, 8-SPT (100 I'M). although GP0531
itself did not bind to adenosine receptors. Thus, GP0531 protects rabbit car-
diac myocytes from ischemia-reperfusion injury by a mechanism involving
enhancement of local ADO and activation of ADO receptors selectively dur-
ing ischemia.
Enhancement of Endogenous Adenosine
Protects Rabbit Cardiac Myocytes from
ischemic Injury
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We assessed the long-term effects of oral vasopressin V1 antagonist, OPC-
21268 (1-1-[4-{3-acetylaminopropoxy)benzoyl]-4-piperidyl-3.4-dihydro-2( 1H)-
quinolinone) in conscious dogs with regional myocardial damage by repeti-
tive DC-shocks. Methods. Study design includes three groups: without DC
shock (e, C, n = 6). DC-shock (., DC, n = 7). and DC-shock with OPC-21268
100 mglkg twice daily (.. , V1 A, n = 7). Cardiac catheterizations were per-
formed at baseline and at 4 and 16 weeks 1 after DC shocks. At sacrifice LV
was fixed with constant pressure and the cavity size was measured. Results.
LVEDP was higher in DC. Mean aortic pressure was lower in V1 A. Stroke
volume did not change among the groups. LV long axis and cross-sectional
cavity area were larger in DC, however, they were significa ntly smaller in Vl A.
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